Buyong Ma1, Jun Zhao2, Ruth Nussinov3. 1. Basic Science Program, Leidos Biomedical Research, Inc., Cancer and Inflammation Program, National Cancer Institute, Frederick, MD 21702, United States. Electronic address: mabuyong@mail.nih.gov. 2. Cancer and Inflammation Program, National Cancer Institute, Frederick, MD 21702, United States. 3. Basic Science Program, Leidos Biomedical Research, Inc., Cancer and Inflammation Program, National Cancer Institute, Frederick, MD 21702, United States; Sackler Inst. of Molecular Medicine, Department of Human Genetics and Molecular Medicine Sackler School of Medicine, Tel Aviv University, Tel Aviv 69978, Israel.
Abstract
BACKGROUND: The dominant feature in neurodegenerative diseases is protein aggregations that lead to neuronal loss. Immunotherapies using antibodies or antibody fragments to target the aggregations are a highly perused approach. The molecular mechanisms underlying the amyloid-based immunotherapy are complex. Deciphering the properties of amyloidogenic proteins responsible for these diseases is essential to obtain insights into antibody recognition of the amyloid antigens. SCOPE OF REVIEW: We systematically explore all available crystal structures of antibody-amyloid complexes related to neurodegenerative diseases, including antibodies that recognize the Aβ peptide, tau protein, prion protein, alpha-synuclein, huntingtin protein (mHTT), and polyglutamine. MAJOR CONCLUSIONS: We found that antibodies mostly use the conformational selection mechanism to recognize the highly flexible amyloid antigens. In particular, solanezumab bound to Aβ12-28 tripeptide motif conformation (F19F20A21), which is shared with the Aβ42 fibril. This motif, which is trapped by the antibody, may provide the missing link in amyloid formation. Water molecules often bridge between the antibody and amyloid, contributing to the recognition. GENERAL SIGNIFICANCE: This paper provides the structural basis for antibody recognition of amyloidogenic proteins. The analysis and discussion of known structures are expected to help in the design and optimization of antibodies in neurodegenerative diseases. This article is part of a Special Issue entitled "System Genetics" Guest Editor: Dr. Yudong Cai and Dr. Tao Huang.
BACKGROUND: The dominant feature in neurodegenerative diseases is protein aggregations that lead to neuronal loss. Immunotherapies using antibodies or antibody fragments to target the aggregations are a highly perused approach. The molecular mechanisms underlying the amyloid-based immunotherapy are complex. Deciphering the properties of amyloidogenic proteins responsible for these diseases is essential to obtain insights into antibody recognition of the amyloid antigens. SCOPE OF REVIEW: We systematically explore all available crystal structures of antibody-amyloid complexes related to neurodegenerative diseases, including antibodies that recognize the Aβ peptide, tau protein, prion protein, alpha-synuclein, huntingtin protein (mHTT), and polyglutamine. MAJOR CONCLUSIONS: We found that antibodies mostly use the conformational selection mechanism to recognize the highly flexible amyloid antigens. In particular, solanezumab bound to Aβ12-28 tripeptide motif conformation (F19F20A21), which is shared with the Aβ42 fibril. This motif, which is trapped by the antibody, may provide the missing link in amyloid formation. Water molecules often bridge between the antibody and amyloid, contributing to the recognition. GENERAL SIGNIFICANCE: This paper provides the structural basis for antibody recognition of amyloidogenic proteins. The analysis and discussion of known structures are expected to help in the design and optimization of antibodies in neurodegenerative diseases. This article is part of a Special Issue entitled "System Genetics" Guest Editor: Dr. Yudong Cai and Dr. Tao Huang.
Authors: Isabel Morgado; Karin Wieligmann; Magdalena Bereza; Raik Rönicke; Katrin Meinhardt; Karthikeyan Annamalai; Monika Baumann; Jessica Wacker; Peter Hortschansky; Miroslav Malešević; Christoph Parthier; Christian Mawrin; Cordelia Schiene-Fischer; Klaus G Reymann; Milton T Stubbs; Jochen Balbach; Matthias Görlach; Uwe Horn; Marcus Fändrich Journal: Proc Natl Acad Sci U S A Date: 2012-07-18 Impact factor: 11.205
Authors: Vladimir N Uversky; Vrushank Davé; Lilia M Iakoucheva; Prerna Malaney; Steven J Metallo; Ravi Ramesh Pathak; Andreas C Joerger Journal: Chem Rev Date: 2014-05-15 Impact factor: 60.622
Authors: Pravas Kumar Baral; Barbara Wieland; Mridula Swayampakula; Magdalini Polymenidou; Muhammad Hafiz Rahman; Nat N V Kav; Adriano Aguzzi; Michael N G James Journal: Acta Crystallogr D Biol Crystallogr Date: 2012-10-18
Authors: Ayisha Siddiqua; Yin Luo; Virginia Meyer; Michael A Swanson; Xiang Yu; Guanghong Wei; Jie Zheng; Gareth R Eaton; Buyong Ma; Ruth Nussinov; Sandra S Eaton; Martin Margittai Journal: J Am Chem Soc Date: 2012-06-12 Impact factor: 15.419
Authors: Erwin De Genst; Dimitri Y Chirgadze; Fabrice A C Klein; David C Butler; Dijana Matak-Vinković; Yvon Trottier; James S Huston; Anne Messer; Christopher M Dobson Journal: J Mol Biol Date: 2015-04-08 Impact factor: 5.469
Authors: Joshua S Ostrander; Justin P Lomont; Kacie L Rich; Vivek Saraswat; Benjamin R Feingold; Megan K Petti; Erin R Birdsall; Michael S Arnold; Martin T Zanni Journal: J Phys Chem Lett Date: 2019-06-27 Impact factor: 6.475